Progenesis is a San Diego-based company founded in 2015 that develops and offers non-invasive genetic tests
for patients on their family planning journey. We offer a variety of services that can be customized to meet
the needs of every patient we serve. The Progenesis team is a motivated group of genetic specialists,
researchers, laboratory professionals, and analysts who are passionate about improving our patients' lives.
As pioneers in genetic screening technologies, our scientists are constantly pursuing research initiatives
to advance our services and expand our understanding of human genetics.
Address: 4150 Regents Park Row Suite 245
La Jolla, CA 92037
As a part of our dedication to our patients, scientists at Progenesis are constantly involved in research to improve our services and products. We have analyzed PGS data from over a thousand patients to estimate probabilities for patients in various age groups to have at least one chromosmally normal (euploid) embryo. We recommend using the number of embryos that will result in at least a 90% chance of obtaining a euploid embryo.
While we cannot guarantee a chromosomally normal embryo, our estimate may serve as a guide. Our findings suggest the number of embryos that will likely result in at least one euploid embryo for egg donors or patients is as follows:
Under 35 years old = 3-5 embryos
Above 35 years old = a minimum of 6 embryos
Maternal Age and Implantation Rate
Embryo implantation rate decreases with maternal age. Patients under 35 years old have a 31% chance of successful implantation, whereas patients over the age of 41 have only 6%. The dramatic decrease in implantation success correlates with chromosomal abnormality. For example, patients under 35 years old have a 54% aneuploidy rate, while patients between 41-42 have an 82% aneuploidy rate. PGT-A testing is performed to increase implantation rate by selecting chromosomally normal embryos.